Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 5/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26923285 | 0.92 | PANK3 (0.38) | OPRL1PANK3HTR6KDM5AKDM4C | |
| SCHEMBL11366020 | 0.91 | NUDT1 (0.43) | OPRL1PANK3HTR6 | |
| SCHEMBL22502738 | 0.88 | OPRL1 (0.45) | OPRL1HTR6KDM5AKDM4CBRD4 | |
| SCHEMBL25085586 | 0.88 | HTR6 (0.51) | HTR6 | |
| SCHEMBL22860585 | 0.87 | OPRL1 (0.46) | OPRL1PANK3HTR6BRD4 | |
| SCHEMBL8774102 | 0.86 | PANK3 (0.38) | OPRL1PANK3HTR6KDM5AKDM4C | |
| SCHEMBL9158929 | 0.86 | PANK3 (0.35) | OPRL1PANK3HTR6KDM5AKDM4C | |
| SCHEMBL8774094 | 0.86 | PANK3 (0.38) | OPRL1PANK3HTR6KDM5AKDM4C | |
| SCHEMBL9158916 | 0.86 | PANK3 (0.35) | OPRL1PANK3HTR6KDM5AKDM4C | |
| SCHEMBL18295013 | 0.85 | SOS1 (0.40) | OPRL1HTR6TRPA1BRD4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059661-A1 | N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-10952978-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952978-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | OPRL1 3720/4885PANK3 4069/4885HTR6 4714/4885 |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | OPRL1 3720/4885PANK3 4069/4885HTR6 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.